Novavax

NVAXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.307 B

$7.95 +2.71%

Close of 7 Aug 2026

Revenue

$1.12B

#1463 by revenue

Earnings

$440.3M

#670 by earnings

Shares outstanding

164,945,726

Latest filing cover page

P/E ratio

3.0

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#41Vir BiotechnologyVIR$1.49B
#42Monte Rosa TherapeuticsGLUE$1.34B
#43NovavaxNVAX$1.31B
#44Inhibrx BiosciencesINBX$1.30B
#45ImmaticsIMTX$1.29B

Where these numbers come from

Share counts and financials for Novavax are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.